

30 April 2010

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products included in the Invitation to Tender dated 21 December 2007, the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009.

Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly.

Product Notification Forms

Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) from 1 June 2010, suppliers are required to notify PHARMAC and the Guild by 4pm **12th May 2010**. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp.

2007/08 Tender

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to an unlisted pharmaceutical – listing for tender winning brand at the tender subsidy will occur on **1 June 2010** and Sole Subsidised Supply commences on **1 September 2010**.

The decision was as follows:

Chemical Name	Presentation; Pack size and type	New tender subsidy	Sole supply brand (Supplier)
Tramadol hydrochloride	Cap 50 mg; 100 capsules, blister	\$6.95	Arrow-Tramadol (Arrow)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tender awarded to a listed pharmaceutical where an alternative brand is already listed – listing of the hospital tender winning brand of the pharmaceutical will occur in Part II of Section H of the Pharmaceutical Schedule on **1 June 2010**; DV Limits and DV pharmaceuticals will apply from **1 August 2010**; delisting of the other brand in Section H will occur on **1 August 2010**.

The decision was as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Tramadol hydrochloride	Cap 50 mg; 100 capsules, blister	Arrow-Tramadol (Arrow)	\$6.95	1%	AFT (AFT) Tramal (CSL Biotherapies) Tramedo (Mylan)

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 21 December 2007.

The decisions were as follows:

Chemical Name	Line Item
Tramadol hydrochloride	Inj 50 mg per ml, 1 ml
Tramadol hydrochloride	Inj 50 mg per ml, 2 ml
Tramadol hydrochloride	Oral liq 100 mg per ml
Tramadol hydrochloride	Tab sustained release 50 mg
Tramadol hydrochloride	Tab sustained release 100 mg
Tramadol hydrochloride	Tab sustained release 150 mg
Tramadol hydrochloride	Tab sustained release 200 mg
Tramadol hydrochloride	Tab sustained release 300 mg

2008/09 Tender

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for the tender winning brand at the tender subsidy will occur on **1 June 2010**, reference pricing of non-tender winning brand will occur on **1 August 2010** and Sole Subsidised Supply will commence on **1 November 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy	New tender subsidy	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Enalapril	Tab 5 mg; 90 tablets, bottle	\$2.19	\$1.98	Arrow-Enalapril 5 (Arrow)	m-Enalapril (Multichem)
Enalapril	Tab 10 mg; 90 tablets, bottle	\$2.76	\$2.44	Arrow-Enalapril 10 (Arrow)	m-Enalapril (Multichem)
Enalapril	Tab 20 mg; 90 tablets, bottle	\$3.68	\$3.24	Arrow-Enalapril 20 (Arrow)	m-Enalapril (Multichem)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

4. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – listing for hospital tender winning brands of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 June 2010**; DV Limits and DV pharmaceuticals will apply from **1 August 2010**; de-listing of other brands in Section H will occur on **1 August 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Enalapril	Tab 5 mg; 90 tablets, bottle	Arrow-Enalapril 5 (Arrow)	\$1.98	1%	m-Enalapril (Multichem) Redopril (Novartis) Renitec (MSD)
Enalapril	Tab 10 mg; 90 tablets, bottle	Arrow-Enalapril 10 (Arrow)	\$2.44	1%	m-Enalapril (Multichem) Redopril (Novartis) Renitec (MSD)
Enalapril	Tab 20 mg; 90 tablets, bottle	Arrow-Enalapril 20 (Arrow)	\$3.24	1%	m-Enalapril (Multichem) Redopril (Novartis) Renitec (MSD)
Irinotecan*	Inj 20 mg per ml, 2 ml; 1 injection, vial	Irinotecan-Rex (Rex Medical)	\$41.00	1%	Camptosar (Pfizer) DBL Irinotecan (Hospira) Irinotecan Actavis 40 (CSL Biotherapies) Mylan (Mylan)

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Irinotecan*	Inj 20 mg per ml, 5 ml; 1 injection, vial	Irinotecan-Rex (Rex Medical)	\$100.00	1%	Camptosar (Pfizer) DBL Irinotecan (Hospira) Irinotecan Actavis 40 (CSL Biotherapies) Mylan (Mylan)

* Irinotecan-Rex will also be listed in Section B of the Pharmaceutical Schedule for PCT only from 1 June 2010. The subsidy of irinotecan inj 1 mg for ECP will reduce from \$3.19 per 1 mg to \$1.04 per 1 mg from 1 August 2010 in Section B of the Pharmaceutical Schedule.

2009/10 Tender

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

5. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on **1 June 2010** and Sole Supply Status commences **1 August 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current Subsidy	New tender subsidy	Sole supply brand (Supplier)
Dexamethasone sodium phosphate	Inj 4 mg per ml, 1 ml; 5 injections, vials	\$21.50	\$21.50	Hospira (Hospira)
Dexamethasone sodium phosphate	Inj 4 mg per ml, 2 ml; 5 injections, ampoules	\$31.00	\$31.00	Hospira (Hospira)

6. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on **1 July 2010** and Sole Supply Status commences **1 October 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current Subsidy	New tender subsidy	Sole supply brand (Supplier)
Bisacodyl	Tab 5 mg; 200 tablets, bottle	\$5.09	\$4.99	Lax-Tab (AFT)
Colchicine	Tab 500 µg; 100 tablets, bottle	\$9.60	\$9.60	Colgout (Aspen)
Cyclophosphamide	Tab 50 mg; 50 tablets, bottle	\$25.71	\$25.71	Cycloblastin (Pfizer)
Dexamethasone	Eye drops 0.1 %; 5 ml OP, bottle	\$4.50	\$4.50	Maxidex (Alcon)
Paraffin liquid with soft white paraffin	Eye oint with soft white paraffin; 3.5 g OP, bottle	\$3.63	\$3.63	Lacri-Lube (Allergan)
Phenoxymethylpenicillin (Penicillin V)	Grans for oral liq 125 mg per 5 ml; 100 ml, bottle	\$1.68	\$1.68	AFT (AFT)
Phenoxymethylpenicillin (Penicillin V)	Grans for oral liq 250 mg per 5 ml; 100 ml, bottle	\$1.82	\$1.78	AFT (AFT)
Rifabutin	Cap 150 mg; 30 capsules, blister	\$213.19	\$213.19	Mycobutin (Pfizer)
Salbutamol	Oral liq 2 mg per 5 ml; 150 ml, bottle	\$2.25	\$1.99	Salapin (AFT)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

7. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes (where applicable) for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on **1 June 2010**; DV Limits and DV Pharmaceuticals will apply from **1 August 2010**

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Dexamethasone sodium phosphate	Inj 4 mg per ml, 1 ml; 5 injections, vials	Hospira (Hospira)	\$21.50	1%	(B)

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Dexamethasone sodium phosphate	Inj 4 mg per ml, 2 ml; 5 injections, ampoules	Hospira (Hospira)	\$31.00	1%	(B)
Vincristine sulphate^	Inj 1 mg per ml, 1 ml; 5 injections, vials	Hospira (Hospira)	\$108.00	1%	(B)
Vincristine sulphate^	Inj 1 mg per ml, 2 ml, 5 injections, vials	Hospira (Hospira)	\$116.00	1%	(B)

^The subsidy of vincristine sulphate inj 1 mg for ECP will reduce from \$21.46 per 1 mg to \$15.77 per 1 mg from 1 June 2010 in Section B of the Pharmaceutical Schedule. The prices for Hospira's vincristine sulphate injections will decrease in Section B of the Pharmaceutical Schedule from 1 June 2010 also.

8. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes (where applicable) for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on **1 July 2010**; DV Limits and DV Pharmaceuticals will apply from **1 September 2010**

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Bisacodyl	Tab 5 mg; 200 tablets, bottle	Lax-Tab (AFT)	\$4.99	1%	Apo-Bisacodyl (Apotex) Dulcolax (Boehringer Ingelheim)
Colchicine	Tab 500 µg; 100 tablets, bottle	Colgout (Aspen)	\$9.60	1%	(B)
Cyclophosphamide	Tab 50 mg; 50 tablets, bottle	Cycloblastin (Pfizer)	\$25.71	1%	Endoxan (Baxter)
Dexamethasone	Eye drops 0.1 %; 5 ml, bottle	Maxidex (Alcon)	\$4.50	1%	(B)
Phenoxymethylpenicillin (Penicillin V)	Grans for oral liq 125 mg per 5 ml; 100 ml, bottle	AFT (AFT)	\$1.68	1%	(B)
Phenoxymethylpenicillin (Penicillin V)	Grans for oral liq 250 mg per 5 ml; 100 ml, bottle	AFT (AFT)	\$1.78	1%	(B)
Rifabutin	Cap 150 mg; 30 capsules, blister	Mycobutin (Pfizer)	\$213.19	1%	(B)
Salbutamol	Oral liq 2 mg per 5 ml; 150 ml, bottle	Salapin (AFT)	\$1.99	1%	Ventolin (GSK)

9. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – listing of the hospital tender winning brand of the pharmaceutical will occur in Part II of Section H of the Pharmaceutical Schedule on **1 June 2010**; DV Limits and DV pharmaceuticals will apply from **1 August 2010**; delisting of the other brand in Section H will occur on **1 August 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Cytarabine**	Inj 500 mg; 1 injection, vial	Pfizer (Pfizer)	\$18.15	1%	Mayne (Hospira)
Cytarabine**	Inj 1 g; 1 injection, vial	Pfizer (Pfizer)	\$37.00	1%	Mayne (Hospira)
Cytarabine**	Inj 2 g; 1 injection, vial	Pfizer (Pfizer)	\$31.00	1%	Mayne (Hospira)

** Pfizer's brand of cytarabine will also be listed in Section B of the Pharmaceutical Schedule for PCT. The subsidy of cytarabine inj 1 mg for ECP will reduce from \$0.30 per 10 mg to \$0.27 per 10 mg from 1 August 2010 in Section B of the Pharmaceutical Schedule.

10. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 June 2010** and DV Limits and DV Pharmaceuticals will apply from **1 August 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
---------------	----------------------------------	----------------------------------	------------	----------	--

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Cytarabine***	Inj 100 mg; 5 injections, vial	Pfizer (Pfizer)	\$76.00	1%	Mayne (Hospira)

*** Pfizer's cytarabine, inj 100 mg, is already listed on Section B of the Pharmaceutical Schedule - the subsidy and price for Pfizer's cytarabine, inj 100 mg will reduce accordingly from 1 June 2010.

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 4 December 2009.

The decisions were as follows:

Chemical Name	Line Item
Ascorbic Acid	Inj 500 mg per 5 ml
Ascorbic Acid	Eye drops 10%
Ascorbic Acid	Tab 50 mg
Beclomethasone Dipropionate	Metered aqueous nasal spray, 50 mcg per dose
Beclomethasone Dipropionate	Metered aqueous nasal spray, 100 mcg per dose
Budesonide	Metered aqueous nasal spray, 50 mcg per dose
Budesonide	Metered aqueous nasal spray, 100 mcg per dose
Dantrolene Sodium	Inj 1 mg per ml, 20 ml
Emtricitabine	Cap 200 mg
Oxycodone Hydrochloride	Cap 5 mg
Oxycodone Hydrochloride	Cap 10 mg
Oxycodone Hydrochloride	Cap 20 mg
Oxycodone Hydrochloride	Inj 10 mg per ml, 1 ml
Oxycodone Hydrochloride	Inj 10 mg per ml, 2 ml
Oxycodone Hydrochloride	Oral liq 5 mg per 5 ml
Oxycodone Hydrochloride	Tab controlled-release 5 mg
Oxycodone Hydrochloride	Tab controlled-release 20 mg
Oxycodone Hydrochloride	Tab controlled-release 40 mg
Oxycodone Hydrochloride	Tab controlled-release 80 mg
Paracetamol	Suppos 125 mg
Paracetamol	Suppos 250 mg
Venlafaxine	Tab immediate-release 12.5 mg
Venlafaxine	Tab immediate-release 25 mg
Venlafaxine	Tab immediate-release 37.5 mg
Venlafaxine	Tab immediate-release 50 mg
Venlafaxine	Tab immediate-release 75 mg
Venlafaxine	Tab immediate-release 100 mg

For the remaining products on the Invitation to Tender dated 21 December 2007, the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock.

We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.